Literature DB >> 29876618

Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?

Benedikt Michael Schaarschmidt1, Johannes Grueneisen2, Vanessa Stebner3, Joachim Klode4,5,6, Ingo Stoffels4,5,6, Lale Umutlu2, Dirk Schadendorf4,5,6, Philipp Heusch7, Gerald Antoch7, Thorsten Dirk Pöppel3.   

Abstract

PURPOSE: To compare the sensitivity and specificity of 18F-fluordesoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), 18F-FDG PET/magnetic resonance (18F-FDG PET/MR) and 18F-FDG PET/MR including diffusion weighted imaging (DWI) in the detection of sentinel lymph node metastases in patients suffering from malignant melanoma. MATERIAL &
METHODS: Fifty-two patients with malignant melanoma (female: n = 30, male: n = 22, mean age 50.5 ± 16.0 years, mean tumor thickness 2.28 ± 1.97 mm) who underwent 18F-FDG PET/CT and subsequent PET/MR & DWI for distant metastasis staging were included in this retrospective study. After hybrid imaging, lymphoscintigraphy including single photon emission computed tomography/CT (SPECT/CT) was performed to identify the sentinel lymph node prior to sentinel lymph node biopsy (SLNB). In a total of 87 sentinel lymph nodes in 64 lymph node basins visible on SPECT/CT, 17 lymph node metastases were detected by histopathology. In separate sessions PET/CT, PET/MR, and PET/MR & DWI were assessed for sentinel lymph node metastases by two independent readers. Discrepant results were resolved in a consensus reading. Sensitivities, specificities, positive predictive values and negative predictive values were calculated with histopathology following SPECT/CT guided SLNB as a reference standard.
RESULTS: Compared with histopathology, lymph nodes were true positive in three cases, true negative in 65 cases, false positive in three cases and false negative in 14 cases in PET/CT. PET/MR was true positive in four cases, true negative in 63 cases, false positive in two cases and false negative in 13 cases. Hence, we observed a sensitivity, specificity, positive predictive value and negative predictive value of 17.7, 95.6, 50.0 and 82.3% for PET/CT and 23.5, 96.9, 66.7 and 82.3% for PET/MR. In DWI, 56 sentinel lymph node basins could be analyzed. Here, the additional analysis of DWI led to two additional false positive findings, while the number of true positive findings could not be increased.
CONCLUSION: In conclusion, integrated 18F-FDG PET/MR does not reliably differentiate N-positive from N-negative melanoma patients. Additional DWI does not increase the sensitivity of 18F-FDG PET/MR. Hence, sentinel lymph node biopsy cannot be replaced by 18F-FDG-PE/MR or 18F-FDG-PET/CT.

Entities:  

Keywords:  DWI; MM; MRI; Malignant melanoma; PET/CT; PET/MRI

Mesh:

Substances:

Year:  2018        PMID: 29876618     DOI: 10.1007/s00259-018-4061-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

1.  Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive Melanoma.

Authors:  Benjamin Y Scheier; Christopher D Lao; Kelley M Kidwell; Bruce G Redman
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

2.  S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version.

Authors:  Annette Pflugfelder; Corinna Kochs; Andreas Blum; Marcus Capellaro; Christina Czeschik; Therese Dettenborn; Dorothee Dill; Edgar Dippel; Thomas Eigentler; Petra Feyer; Markus Follmann; Bernhard Frerich; Maria-Katharina Ganten; Jan Gärtner; Ralf Gutzmer; Jessica Hassel; Axel Hauschild; Peter Hohenberger; Jutta Hübner; Martin Kaatz; Ulrich R Kleeberg; Oliver Kölbl; Rolf-Dieter Kortmann; Albrecht Krause-Bergmann; Peter Kurschat; Ulrike Leiter; Hartmut Link; Carmen Loquai; Christoph Löser; Andreas Mackensen; Friedegund Meier; Peter Mohr; Matthias Möhrle; Dorothee Nashan; Sven Reske; Christian Rose; Christian Sander; Imke Satzger; Meinhard Schiller; Heinz-Peter Schlemmer; Gerhard Strittmatter; Cord Sunderkötter; Lothar Swoboda; Uwe Trefzer; Raymond Voltz; Dirk Vordermark; Michael Weichenthal; Andreas Werner; Simone Wesselmann; Ansgar J Weyergraf; Wolfgang Wick; Claus Garbe; Dirk Schadendorf
Journal:  J Dtsch Dermatol Ges       Date:  2013-06       Impact factor: 5.584

3.  Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II.

Authors:  I Stoffels; J Dissemond; A Körber; U Hillen; T Poeppel; D Schadendorf; J Klode
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-03       Impact factor: 6.166

4.  Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.

Authors:  Jeffrey D Wagner; Donald Schauwecker; Darrell Davidson; Theodore Logan; John J Coleman; Gary Hutchins; Charlene Love; Stacie Wenck; Joanne Daggy
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

5.  Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging.

Authors:  Ingo Stoffels; Stefan Morscher; Iris Helfrich; Uwe Hillen; Julia Leyh; Julia Lehy; Neal C Burton; Thomas C P Sardella; Jing Claussen; Thorsten D Poeppel; Hagen S Bachmann; Alexander Roesch; Klaus Griewank; Dirk Schadendorf; Matthias Gunzer; Joachim Klode
Journal:  Sci Transl Med       Date:  2015-12-09       Impact factor: 17.956

6.  Adverse reactions to patent blue V dye - The NEW START and ALMANAC experience.

Authors:  L Barthelmes; A Goyal; R G Newcombe; F McNeill; R E Mansel
Journal:  Eur J Surg Oncol       Date:  2009-11-24       Impact factor: 4.424

7.  Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II.

Authors:  Astrid M Fink; Sylvia Holle-Robatsch; Nicole Herzog; Siroos Mirzaei; Klemens Rappersberger; Nikolaus Lilgenau; Wolfgang Jurecka; Andreas Steiner
Journal:  Melanoma Res       Date:  2004-04       Impact factor: 3.599

8.  Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.

Authors:  Carolin Riegger; Angela Koeninger; Verena Hartung; Friedrich Otterbach; Rainer Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch; Till A Heusner
Journal:  Acta Radiol       Date:  2012-09-22       Impact factor: 1.990

9.  Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.

Authors:  Claus Garbe; Axel Hauschild; Matthias Volkenandt; Dirk Schadendorf; Wilhelm Stolz; Uwe Reinhold; Rolf-Dieter Kortmann; Christoph Kettelhack; Bernhard Frerich; Ulrich Keilholz; Reinhard Dummer; Günther Sebastian; Wolfgang Tilgen; Gerold Schuler; Andreas Mackensen; Roland Kaufmann
Journal:  Melanoma Res       Date:  2008-04       Impact factor: 3.599

10.  Correlation of standardized uptake value and apparent diffusion coefficient in integrated whole-body PET/MRI of primary and recurrent cervical cancer.

Authors:  Johannes Grueneisen; Karsten Beiderwellen; Philipp Heusch; Paul Buderath; Bahriye Aktas; Marcel Gratz; Michael Forsting; Thomas Lauenstein; Verena Ruhlmann; Lale Umutlu
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

View more
  4 in total

Review 1.  Precision Nuclear Medicine: The Evolving Role of PET in Melanoma.

Authors:  Chadwick L Wright; Eric D Miller; Carlo Contreras; Michael V Knopp
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

Review 2.  Imaging of pediatric cutaneous melanoma.

Authors:  Sue C Kaste
Journal:  Pediatr Radiol       Date:  2019-10-16

3.  CT diagnosis of ilioinguinal lymph node metastases in melanoma using radiological characteristics beyond size and asymmetry.

Authors:  M J Wilkinson; H Snow; K Downey; K Thomas; A Riddell; N Francis; D C Strauss; A J Hayes; M J F Smith; C Messiou
Journal:  BJS Open       Date:  2021-01-08

4.  Value of 18F-FDG Hybrid PET/MR in Differentiated Thyroid Cancer Patients with Negative 131I Whole-Body Scan and Elevated Thyroglobulin Levels.

Authors:  Hongyan Li; Xiaomin Chen; Yajing Zhang; Kun Wang; Zairong Gao
Journal:  Cancer Manag Res       Date:  2021-03-29       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.